Overview

Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma

Status:
Completed
Trial end date:
2011-05-17
Target enrollment:
Participant gender:
Summary
The main objective of the trial is to document the progression free survival (PFS) in advanced or metastatic small cell lung carcinoma (SCLC) patients previously treated with at least one therapeutic regimen
Phase:
Phase 2
Details
Lead Sponsor:
AGC Biologics S.p.A.
MolMed S.p.A.
Treatments:
Doxorubicin
Liposomal doxorubicin